D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy

The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy

This is a sigle-center, prospective study to evaluate the role of D-Dimer testing in patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy.

Patients with atrial fibrillation receiving Dabigatran or warfarin anticoagulation therapy was screened and signed to two group: Dabigatran group and Warfarin group. D-dimer test was analyzed before and 3 months after anticoagulation starting specificly. Patients were followed-up for at least 12 months,and clinical outcomes, including thrombotic events major bleeding events and all-cause deaths were recorded during follow-up period.

Inclusion Criteria:

• Non-valvular atrial fibrillation
• Receiving oral anticoagulation therapy and have good compliance

Exclusion Criteria:

• Life expectancy less than 1 year
• Thrombosis or major bleeding history within 3 months
• Refusal to Participate